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Dysregulation of the mitochondrial network in termi-
nally differentiated cells contributes to a broad spec-
trum of disorders. Methylmalonic acidemia (MMA) is 
an autosomal recessive inborn error of intermediary 
metabolism caused by the deficiency of methylmalo-
nyl-CoA mutase (MMUT) — a mitochondrial enzyme 
that mediates the degradation of certain amino acids 
and lipids. The loss of MMUT activity triggers an accu-
mulation of toxic endogenous metabolites causing se-
vere organ dysfunctions and life-threatening complica-
tions. How MMUT deficiency instigates mitochondrial 
distress and tissue damage remains poorly understood. 
Using cell and animal-based models, we recently dis-
covered that MMUT deficiency disables the PINK1-
induced translocation of PRKN/Parkin to MMA-
damaged mitochondria, impeding their delivery and 
subsequent dismantling by macroautopha-
gy/autophagy-lysosome degradation systems (Luciani 
et al. Nat Commun. 11(1):970). This promotes an ac-
cumulation of damaged and/or dysfunctional mito-
chondria that spark epithelial distress and tissue dam-
age. Using a systems biology approach based on drug-
disease network perturbation modeling, we predicted 
targetable pathways, whose modulation repairs mito-
chondrial dysfunctions in patient-derived kidney cells 
and ameliorates disease-relevant phenotypes in mmut-
deficient zebrafish. These results unveil a link between 
primary MMUT deficiency, defective mitophagy, and 
cell distress, offering promising therapeutic avenues 
for MMA and other mitochondria-related diseases. 
 
 
Mitochondria — the intracellular powerhouse that stores 
energy and signaling metabolites — are highly dynamic, 
double-membrane organelles that enact metabolism, 
hence sustaining physiology and organismal health. The 
maintenance of these functionally pleiotropic organelles is 
particularly relevant in terminally differentiated cells that 
are highly dependent on aerobic metabolism. Disruption of 
the mitochondrial network function and homeostasis 
might therefore confer a potentially devastating vulnerabil-
ity to many different cell types, culminating in a broad 
spectrum of diseases. 
Organic acidemias constitute a large group of inherited, 
life-threatening disorders of intermediary metabolism, 
mostly caused by deficiencies in enzymes that coordinate 
the amino acid degradation. Methylmalonic acidemia 
(MMA; MIM #251000) — the most common form of organ-
ic acidemias — is due to recessive, inactivating mutations 
in the MMUT gene encoding methylmalonyl-CoA mutase 
(MMUT) — a (vitamin B12-dependent) mitochondrial en-
zyme that catabolizes branched chain amino acids and 
certain lipids to succinyl-CoA, thereby feeding the tricar-
boxylic acid (TCA) cycle and energy metabolism. Complete 
or partial deficiency of MMUT activity (MMUT0 and MMUT- 
subtypes, respectively) results in the accumulation of toxic 
organic acids (e.g., methylmalonic acid, propionic acid and 
2-methylcitric acid), leading to abnormalities in the mito-
chondrial network that drive systemic organ dysfunctions 
affecting primarily the brain, eye, liver and kidney. Howev-
er, mechanistically, how the enzyme deficiency begets mi-
tochondrial distress and cell toxicity remains unclear. 
As MMUT is robustly expressed within the mitochon-
dria of kidney tubular cells, we first investigated the conse-
quences of MMUT deficiency on the function and homeo-
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lyzed the properties of mitochondria in kidney tubular cells 
derived from the urine of either healthy controls or MMA 
patients harboring loss-of-function mutations in MMUT. 
Compared to control cells, MMA patient-derived kidney 
tubular cells (hereafter referred to as MMA cells) exhibit an 
accumulation of damaged and fragmented mitochondria 
that aberrantly generate a large amount of reactive oxygen 
species (ROS) and epithelial cell distress. These dysfunc-
tions are associated with an exaggerated production of 
LCN2 (lipocalin 2) — a small iron-transporting protein 
largely produced by kidney tubular cells following cellular 
damage. Such mitochondrial phenotypes are also con-
firmed in mouse kidney tubule cells following conditional 
inactivation of Mmut or in the kidney of mice carrying a 
mutant Mmut allele (p.Met698Lys, corresponding to the 
patient mutation p.Met700Lys) and a knock-out Mmut 
allele (hereafter referred to as MmutKI/KO mice), demon-
strating the key role of MMUT in preserving the mitochon-
drial network homeostasis and function. However, despite 
the metabolic and mitochondrial abnormalities, the 
MmutKI/KO mice develop no structural changes nor intersti-
tial inflammation nor significant kidney failure nor changes 
in LCN2 levels in kidneys as well as in plasma and/or urine 
— even in aged mutant mice — thus failing to recapitulate 
the kidney disease associated with MMA. 
To overcome this hurdle, we established the first 
mmut-knockout zebrafish model using CRISPR/Cas9 ge-
nome editing. The zebrafish model stands out for a highly 
conserved integrative physiology, with recognizable organ 
systems performing the same physiological functions as 
their mammalian counterparts. For instance, the pattern-
ing of the kidney tubule is remarkably conserved in the 
zebrafish pronephros, including junctional complexes, a 
high density of mitochondria and well-developed endoly-
sosomal system, and endocytic receptors and transporters. 
Furthermore, zebrafish possess orthologues of human dis-
ease-associated genes, including disorders of metabolism 
and physiology, while retaining the opportunities to per-
form (high-throughput) phenotypic screens in an in vivo 
context. 
Analogous to metabolic and mitochondrial alterations 
reported in patient-derived and Mmut-deleted kidney cells, 
we noted that both MMA-accumulating liver and kidney of 
mmut‒deficient zebrafish display altered mitochondrial 
morphology characterized by increased mitochondrial cir-
cularity with perturbed cristae organization. Seahorse 
metabolic flux analyses reveal impaired mitochondrial bio-
energetics in mmut–deficient zebrafish when compared to 
control larvae. These changes are paralleled by a major 
mitochondrial oxidative stress, as testified by in vivo imag-
ing and ratiometric confocal microscopy-based analyses of 
glutathione redox fluorescent signals in liver Grx1-roGFP2-
labeled mitochondria, demonstrating the evolutionary 
conservation of this connection. Mutant zebrafish faithfully 
recapitulate MMA characteristic disease-relevant pheno-
types, such as liver mitochondriopathy, behavioural ab-
normalities, and an excess of mortality. These latter phe-
notypes are rescued by feeding the mutant zebrafish with 
a low protein diet — a current supportive care strategy 
used in MMA patients as it prevents the accumulation of 
methylmalonic acid and possibly other toxic endogenous 
metabolites. Likewise, morphologically abnormal mito-
chondria were also described in kidney tubules and ex-
planted livers of patients with MMA, strongly suggesting a 
link between mitochondrial dysfunctions and quality con-
trol/surveillance systems in the pathogenesis of disease. 
Mammalian cells have evolved quality control and sur-
veillance strategies to maintain the mitochondrial network 
homeostasis and function. These salvaging pathways rely 
on the execution of an evolutionary conserved, dynamic, 
and self-regulating mechanism called macroautopha-
gy/autophagy that culminates in the endolysosome–
mediated degradation of potentially dangerous cytosolic 
entities (e.g., misfolded proteins and worn out organelles, 
and invading pathogens). Mitochondrial autopha-
gy/mitophagy, wherein damaged and/or dysfunctional 
mitochondria are sequestered within autophagosomes and 
delivered to endolysosomes for degradation, is selectively 
instigated by the recruitment and activation of the mito-
chondrial serine/threonine protein kinase PINK1 and E3-
ubiquitin-protein ligase Parkin/PRKN to the outer mito-
chondrial membrane. Prolonged and/or unrepairable dam-
age to the mitochondrial network might thus trigger the 
PINK1-PRKN pathway, driving multiple signalling events 
that culminate in the engulfment and hence degradation of 
damaged mitochondria by endolysosomes. Given the ac-
cumulation of MMA-affected mitochondria and higher 
numbers of autophagic vesicles, we hypothesized that the 
deficiency of the enzyme MMUT might sabotage the 
PINK1-PRKN-mediated priming of MMA diseased mito-
chondria and hence their delivery to autophagy–lysosome 
degradation pathways. Using the translocation of PRKN to 
mitochondria as a bona fide reporter of PINK1-PRKN-
dependent priming mechanisms, we observed that MMA 
cells display a decrease in numbers of PRKN+ clusters and 
translocation of PRKN to damaged mitochondria, in both 
normal and stress-induced conditions. As a direct conse-
quence of defective PINK1-PRKN priming mechanisms, 
mutant cells fail to deliver their damaged mitochondria to 
autophagy-lysosome degradation systems, as evidenced by 
the sensitive mt-Keima imaging-based assay and electron 
microscopy. This triggers an accumulation of MMA-
diseased mitochondria, as indicated by a marked increase 
in overall mitochondrial proteins and ratio between mt-
DNA and n-DNA under both normal and mitophagy-
induced conditions. Expression of the wild-type PINK1 in 
MMA cells activates mitophagy-mediated degradation of 
diseased mitochondria, thereby averting mitochondria-
derived epithelial distress and cell damage. Conversely, in 
human haploid HAP-1 cells, CRISPR/Cas9-mediated knock-
out of PINK1 or PRKN2 provokes mitochondrial alterations 
that are similar to, albeit milder than, those encountered in 
patient derived- and in Mmut-deleted kidney cells. These 
findings suggest that anomalies in PINK1/Parkin-mediated 
quality control and surveillance systems might thus inter-
sect the mitochondrial alterations induced by MMUT defi-
ciency to reach a high level of mitochondrial dysfunction 
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that ultimately contributes to the pathogenesis in 
methylmalonic acidemia patients (Figure 1). 
Isolated methylmalonic acidemias make up one of the 
most frequent groups of inborn errors of metabolism, 
which often manifest in early childhood and are associated 
with high morbidity and mortality. There are no curative 
treatments for MMA and the available therapeutic ap-
proaches can substantially decrease mortality and the 
overall morbidity but in most cases cannot completely pre-
vent long-term complications. Therefore, there is an urgent 
need to yield promising targetable interventions in the 
early course of MMA.  
Introducing a drug-disease network-based computa-
tional modeling approach (Mantra 2.0; Mode of Action by 
Network Analysis; http://mantra.tigem.it; Figure 1), we 
identified druggable pathways that might potentially re-
verse cellular dysfunctions associated with MMA. This 
cheminformatics modeling elucidates genome-wide tar-
getable candidates by systematically matching disease 
gene signature, here derived from the comparison of ex-
pression profiles between MMA and their related control 
cells, against the Connectivity Map (CMAP) library of 1309 
small bioactive drug compounds that are available for re-
purposing. Predictions for drug-disease pairs were based 
on the hypothesis that, if a drug reverses the disease gene 
signature, that drug might potentially target disease-
relevant biological pathways. These in silico analyses indi-
cate that targeting mitochondrial function and redox ho-
meostasis might reverse disease phenotypes associated 
with MMUT deficiency. Inspired by the biological evidence 
and MANTRA predictions, we tested whether mitochon-
dria-targeted interventions (e.g., mito-TEMPO and/or Mi-
toQ), which rescue mitochondria-derived cell dysfunctions 
associated with the lysosome storage disease cystinosis, 
might correct disease-relevant phenotypes induced by 
MMUT deficiency. Treatment of MMA cells with mito-
TEMPO partially restores mitochondrial network homeo-
stasis and improves its function, normalizes mitochondrial 
FIGURE 1: Pathophysiology and identification of druggable targets in methylmalonic acidemia. In MMA-affected kidney cells and 
zebrafish, deficiency of the enzyme MMUT and the resulting accumulation of toxic organic acids trigger mitochondrial alterations that are 
characterized by a collapse of the mitochondrial membrane potential (ΔΨm), abnormal bioenergetics profiling, and increased generation of 
mitochondrial ROS and oxidative stress. Faulty execution of PINK1-PRKN-mediated mitophagy induced by MMUT deficiency impedes the 
delivery of damaged mitochondria and their dismantling by autophagy‒lysosome degradation systems. This leads to the accumulation of 
dysfunctional, ROS-overproducing mitochondria that ultimately trigger epithelial distress (as evidenced by LCN2 overproduction) in patient-
derived cells and disease-relevant phenotypes (as testified by liver/kidney mitochondriopathy, behavioral abnormalities and an excess of 
mortality) in mmut-deficient zebrafish. Unbiased drug–disease network perturbation modelling, based on transcriptome−wide profiles from 
MMA patient‒derived kidney cells against a large compendium of gene signatures derived from Connectivity Map (CMAP) library of 1309 
small bioactive drug compounds 1309 small bioactive drug compounds, identifies targetable disease-relevant biological pathways. Modula-
tion of these identified targets (e.g., treatment with mitochondria‒targeted ROS scavengers mito-TEMPO or MitoQ) repairs mitochondrial 
dysfunctions, neutralizes epithelial stress and cell damage in MMA cells, and improves disease–relevant phenotypes in mmut–deficient 
zebrafish. 
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ROS and autophagy markers, and prevents epithelial dis-
tress and cell damage. Furthermore, treatment with low 
doses of MitoQ alleviates the mitochondrial oxidative 
stress, ameliorates behavioral phenotypes and blunts the 
excessive mortality in the mmut-deficient zebrafish model 
of MMA. Importantly, both pharmacological interventions 
did not modify the levels of MMA metabolite in either 
MMA cells or mmut‒deficient zebrafish, supporting the 
concept that mitochondrial targeting acts independently of 
the elevation of toxic MMA metabolites (1).  
In conclusion, we identified a pathway that links a pri-
mary deficiency of a mitochondrial enzyme with dysfunc-
tion of mitophagy, accumulation of diseased mitochondria, 
and epithelial distress and tissue damage. These findings 
reveal a heretofore undescribed role of the enzyme MMUT 
— beyond its function in cellular metabolism — in preserv-
ing mitochondrial quality control systems and hence the 
integrity of specialized epithelial cells. Antioxidant com-
pounds specifically targeting mitochondria offer novel 
therapeutic strategies for repairing mitochondria in MMA 
and other mitochondria-related disorders. 
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